Who
Georges Gemayel
Director
Company insider
Files Form 4 as: Executive Chair of the Board, Disc Medicine; Director, Supernus Pharmaceuticals; Director, Momenta Pharmaceuticals; Director, Dimension Therapeutics; Director, Raptor Pharmaceutical; Director, Nps Pharmaceuticals; Director, Adolor; President & CEO, Altus Pharmaceuticals.
In numbers
- Trades disclosed
- 166
- Buys
- 2
- Sells
- 9
- Bought
- $339K
- Sold
- $7.1M
- Companies
- 9
- Companies where not an officer
- 6
- First trade
- 28 Dec 2005
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,212 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,212 at $0.00 | filing |
| 6 Mar 2026filed 9 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $200K7,905 at $25.30 | filing |
| 6 Mar 2026filed 9 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $466K8,787 at $53.00 | filing |
| 6 Mar 2026filed 9 Mar 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —7,905 at $0.00 | filing |
| 6 Mar 2026filed 9 Mar 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —7,905 at $0.00 | filing |
| 6 Mar 2026filed 9 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $200K7,905 at $25.30 | filing |
| 6 Mar 2026filed 9 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $466K8,787 at $53.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $537K10,000 at $53.71 | filing |
| 5 Mar 2026filed 9 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $537K10,000 at $53.71 | filing |
| 24 Feb 2026filed 25 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,475 at $0.00 | filing |
| 24 Feb 2026filed 25 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —4,475 at $0.00 | filing |
| 24 Feb 2026filed 25 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —4,475 at $0.00 | filing |
| 24 Feb 2026filed 25 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,475 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $195K15,000 at $12.98 | filing |
| 23 Feb 2026filed 25 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $195K15,000 at $12.98 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,989 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —4,977 at $0.00 | filing |
News
Supernus Pharmaceuticals (NASDAQ:SUPN) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Critical SurveySUPN · tickerreport.com · 11 Oct 2026Shineco (NASDAQ:SISI) vs. Supernus Pharmaceuticals (NASDAQ:SUPN) Financial AnalysisSUPN · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Georges Gemayel; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.